biostudies-literatureUnknown21(8)Hsieh TC<h4>Introduction</h4>This study examined the association between metformin-based oral antihyperglycemic combination therapy and the risk of developing dementia in patients with newly diagnosed type 2 diabetes mellitus (T2DM).<h4>Methods</h4>We conducted a retrospective cohort study using data from a random sample of 2,000,000 individuals in Taiwan's National Health Insurance Research Database from 2000 to 2018. A total of 44,073 patients with newly diagnosed T2DM were identified and categorized into four groups based on initial treatment: metformin (MET)-sulfonylureas (SU), MET-dipeptidyl peptidase-4 inhibitor (DPP4i), MET-thiazolidinedione (TZD), and MET-glinides. The participants were followed until December 2018.<h4>Results</h4>The hazard ratio of MET-TZD was 0.73 (95% confidence intervAlzheimer's & dementia : the journal of the Alzheimer's Associatione70590https://www.ebi.ac.uk/biostudies/studies/S-EPMC12358239biostudies-literatureMetformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.PMC12358239Hsieh TCChen HHChang WCHo CPfalseMetformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.<h4>Introduction</h4>This study examined the association between metformin-based oral antihyperglycemic combination therapy and the risk of developing dementia in patients with newly diagnosed type 2 diabetes mellitus (T2DM).<h4>Methods</h4>We conducted a retrospective cohort study using data from a random sample of 2,000,000 individuals in Taiwan's National Health Insurance Research Database from 2000 to 2018. A total of 44,073 patients with newly diagnosed T2DM were identified and categorized into four groups based on initial treatment: metformin (MET)-sulfonylureas (SU), MET-dipeptidyl peptidase-4 inhibitor (DPP4i), MET-thiazolidinedione (TZD), and MET-glinides. The participants were followed until December 2018.<h4>Results</h4>The hazard ratio of MET-TZD was 0.73 (95% confidence interv2025-01-01T00:00:00Z2025 Aug2026-04-13T17:07:21.278Z2026-04-07T13:36:55.619ZS-EPMC123582394082006910.1002/alz.70590